Liquidia Technologies, a privately held biopharmaceutical company developing
particle-based vaccines and therapeutics, announced today that Frank J. Malinoski,
M.D., Ph.D., has joined the company as Chief Medical Officer.
Dr. Malinoski has more than 20 years of executive experience in the biotech
and pharmaceutical industries, including work in clinical development, regulatory
evaluation and post-approval oversight for numerous vaccines and immunotherapy
products. In his position, Dr. Malinoski will be responsible for clinical strategy
and regulatory affairs across Liquidia's product platform.
"We are extremely pleased to have Frank join our leadership team,"
said Neal Fowler, Liquidia's Chief Executive Officer. "Frank's
scientific expertise and impressive track record developing and commercializing
successful vaccines will be invaluable as we advance our initial vaccine candidate
through clinical trials and expand our pipeline of vaccine and therapeutic products."
Dr. Malinoski brings to Liquidia an extensive background in the fields of vaccines,
immunology, oncology, infectious disease and other key therapeutic areas. He
has held senior positions in clinical research, business development and medical
affairs at Wyeth, MedImmune, Nabi and several other biopharmaceutical companies.
Dr. Malinoski began his career in the military, serving in clinical research
and development of vaccines against infectious disease threats. Dr. Malinoski
received his B.A. from Colby College, his M.D. from Albany Medical College and
his Ph.D. in microbiology from Rutgers University.
Posted February 19th, 2010